IN CYTU, INC.

LINCOLN, RI · Founded 2007 · Biotech · Private

Cellarium, an active specific immunotherapeutic vaccine for glioma treatment combining biological cofactors and patient-specific tumor cell lysate to stimulate dendritic cell-mediated immune response

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
LINCOLN, RI
Founded
2007
Latest Form D
$1.9M, Jan 2012
Total capital
$5.5M
Federal grants
$879K
1 award · 2016
Rank in peer group#25 of 502
Private capital raised
$4.6M
2 Form D · last Jan 2012
178 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20092010201120122013201420152016FEDERAL ↑EQUITY ↓Cumulative $5.5M$879K1st Form D$2.8M2nd Form D$1.9M
2009201120132015FEDERAL ↑EQUITY ↓Cumulative $5.5M$879K1st Form D$2.8M2nd Form D$1.9M

Latest events

  • Federal grantHealth and Human S · Phase II · Advancing a Glioma Immunotherapy$879K
  • Private capital raisedForm D · SEC · 2nd filing$1.9M
  • Private capital raisedForm D · SEC · 1st filing$2.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#25 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Alfred V VasconcellosExecutive Officer, DirectorNamed in SEC Form D filings
  • David V CohenDirectorNamed in SEC Form D filings
  • David MooneyDirectorNamed in SEC Form D filings
  • John G. PicerneDirectorNamed in SEC Form D filings
  • Richard BerensonExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Prox Capital Holdings, LLCSimilar federal contract value in Biotech · null in contracts
  • Parabilis MedicinesSimilar federal contract value in Biotech · null in contracts
  • Mozart TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • VXBIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
  • LONGEVERON, LLCSimilar federal contract value in Biotech · null in contracts
  • EnKay Omics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .